PIMJS
VKTX icon

PKO Investment Management Joint-Stock’s Viking Therapeutics VKTX Stock Holding History

PKO Investment Management Joint-Stock’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$352K – 234
2025
Q4 		$352K Hold
10,000
– – 0.03% 197
2025
Q3 		$263K Hold
10,000
– – 0.02% 194
2025
Q2 		$265K Sell
10,000
-5,000
-33% -$132K 0.03% 169
2025
Q1 		$362K Hold
15,000
– – 0.04% 163
2024
Q4 		$604K Buy
+15,000
New +$855K 0.08% 132

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PKO Investment Management Joint-Stock's VKTX Position: Q1 2026 in Review

PKO Investment Management Joint-Stock sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $352K sold.

PKO Investment Management Joint-Stock first reported a position in VKTX in Q4 2024 and held it in 5 quarters. The position peaked at $604K in Q4 2024. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • PKO Investment Management Joint-Stock reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PKO Investment Management Joint-Stock sold 10,000 Viking Therapeutics shares in Q1 2026, an estimated $352K.
  • PKO Investment Management Joint-Stock first reported a position in Viking Therapeutics in Q4 2024 and held it in 5 quarters.
  • PKO Investment Management Joint-Stock's Viking Therapeutics position peaked at $604K in Q4 2024.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on PKO Investment Management Joint-Stock's 13F filing for Q1 2026, filed 17 Apr 2026.